This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Amolyt Pharma. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: The Innovations of Stephane Milano
Introduction
Stephane Milano is a notable inventor based in Saint Nizier d'Azergues, France. He has made significant contributions to the field of metabolic disorder treatments through his innovative research and development. His work primarily focuses on the heparin-binding domain of insulin-like growth factor binding protein-2 (IGFBP-2).
Latest Patents
Milano holds 1 patent for his invention titled "Heparin-binding domain of IGFBP-2 in the treatment of metabolic disorders." This technology relates to compounds, particularly peptides that comprise the heparin-binding domain of IGFBP-2. These compounds are designed for the modulation of metabolic disorders. The patent also covers the uses of such compounds in methods for preventing and treating metabolic disorders, as well as in compositions and formulations for these uses.
Career Highlights
Stephane Milano is currently associated with Amolyt Pharma, where he continues to advance his research in metabolic disorders. His work has the potential to significantly impact the treatment landscape for individuals suffering from these conditions.
Collaborations
Milano has collaborated with notable professionals in his field, including Thierry Abribat and Thomas Delale. These partnerships have likely contributed to the success and development of his innovative ideas.
Conclusion
Stephane Milano's contributions to the field of metabolic disorder treatments through his patent and work at Amolyt Pharma highlight his role as an influential inventor. His research continues to pave the way for advancements in medical treatments.